Journals / Respiratory Case Reports / 2022 / Cilt: 11 - Sayı: 2

Atypical Post-COVID Sequel: Bronchiectasis

Atipik Post-COVID Sekeli: Bronşektazi

Pages
112–115
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the coming years, one of the first questions raised regarding the etiology of bronchiectasis may be the patient’s COVID-19 history.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Although there have been many studies determining the occurrence of post-COVID pulmonary fibrosis and thromboembolism, there are a limited number of studies and case reports in literature on the development of bronchiectasis.
📊
Key Findings & Data:The present study presents a case of bronchiectasis sequel in the post-COVID 11th month.
💡
Conclusion & Impact:In the coming years, one of the first questions raised regarding the etiology of bronchiectasis may be the patient’s COVID-19 history.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Although there have been many studies determining the occurrence of post-COVID pulmonary fibrosis and thromboembolism, there are a limited number of studies and case reports in literature on the development of bronchiectasis. The present study presents a case of bronchiectasis sequel in the post-COVID 11th month. A 49-year-old male, non-smoker with diabetes mellitus and hypertension was admitted with exertional dyspnea. The patient had been followed up in the hospital 11 months earlier for 1.5 months with severe COVID-19 pneumonia and respiratory failure for which he was treated with Favipiravir, pulse methylprednisolone and broad-spectrum antibiotics. There was no need for invasive mechanical ventilation, and no secondary bacterial infection was detected. Compared to the previous CT, a chest CT revealed that bronchiectasis had persisted despite the disappearance of fibrotic changes. In the coming years, one of the first questions raised regarding the etiology of bronchiectasis may be the patient’s COVID-19 history.

Özet

Post- COVID pulmoner fibrozis ve tromboemboli gelişimine dair çok sayıda yayın olmasına rağmen, bronşektazi gelişimi ile ilgili literatürde sınırlı sayıda yayın ve olgu sunumları bulunmaktadır. Biz de bu çalışmamızda post-COVID 11. ayda bronşektazi sekeli saptanan olgumuzu sunmayı amaçladık. Kırk dokuz yaşında, erkek, diabetes mellitus ve hipertansiyon tanılı, non-smoker hasta, efor dispnesi ile başvurdu. On bir ay önce ağır COVID-19 pnömonisi ve solunum yetmezliği ile hastanede 1,5 ay süreyle yatırılarak izlenmişti. Favipiravir, pulse metilprednizolon ve geniş spekturumlu antibiyotik verilen hastanın invazif mekanik ventilatör ihtiyacı olmamıştı ve sekonder bakteriyel enfeksiyon saptanmamıştı. Toraks BT‘sinde eski BT’leri ile kıyaslandığında fibrotik değişiklikler kaybolmasına rağmen bronşektazisinin sebat ettiği görüldü. Gelecek yıllarda bronşektazi etyolojisinde ilk sorgulayacağımız nedenlerden biri COVID- 19 geçirme öyküsü olabilir.

🔖

Cite This Article

AFŞİN, E. (2022). Atypical Post-COVID Sequel: Bronchiectasis. Respiratory Case Reports, Cilt: 11 - Sayı: 2, 112–115. https://ajindex.com/articles/588856

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ambrosetti MC, Battocchio G, Zamboni GA, Fava C, Tacconelli E, Mansueto G. Rapid onset of bronchiectasis in COVID-19 Pneumonia: two cases studied with CT. Radiol Case Rep 2020
  2. [CrossRef] 2. Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax 2019
  3. 74(Supll 1):1-69. [CrossRef] 3. Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017
  4. 50(3):1700629. [CrossRef] 4. Sayır F, Çobanoğlu U, Mergan D. İlginç bir bronşektazi olgusu. Van Tıp Dergisi 2011
  5. Apriningsih H, Prabowo NA, Ardyanto TD, Reviono, Pradana RF. Bronchiectasis as A Sequelae From COVID-19. Proeceeding of the 4th International Conference on Sustainable Innovation 2020-Health Science and Nursing (ICoSIHSN 2020). 2021
  6. [CrossRef] 6. King P. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 2009
  7. [CrossRef] 7. Fraser E. Long term respiratory complications of covid-19. BMJ 2020
  8. m3001. [CrossRef] 8. Fang Y, Zhang H, Xu Y, Xie J, Pang P, Ji W. CT Manifestations of two cases of 2019 novel Coronavirus (2019- nCoV) pneumonia. Radiology 2020
  9. [CrossRef] 9. Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020
  10. 100463. [CrossRef] 10. José RJ, Manuel A, Gibson-Bailey K, Lee L. Post COVID- 19 bronchiectasis: a potential epidemic within a pandemic. Expert Rev Respir Med 2020
  11. [CrossRef] 11. Bernheim A, Mei X, Huang M, Yang Y, Fayad ZA, Zhang N, et al. Chest CT findings in Coronavirus disease-19 (COVID-19): Relationship to duration of infection. Radiology 2020
  12. 200463. [CrossRef] 12. Suliman AM, Bitar BW, Farooqi AA, Elarabi AM, Aboukamar MR, Abdulhadi AS. COVID-19-associated bronchiectasis and its impact on prognosis. Cureus 2021
  13. e15051. [CrossRef] 13. Oh JY, Lee YS, Min KH, Hur GY, Lee SY, Kang KH, et al. Elevated interleukin-6 and bronchiectasis as risk factors for acute exacerbation in patients with tuberculosisdestroyed lung with airflow limitation. J Thorac Dis 2018
  14. [CrossRef] 14. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines